Shots:

• The approval is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT as monothx. in 403 patients in ratio (1:1) with (ES-SCLC)
• The P-III IMpower133 study results: mOS (12.3 vs 10.3 mos.); PFS (5.2 vs 4.3 mos.); safe & effective results with improvement in survival rates
• Tecentriq is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptor and is evaluated in nine P-III trial for lungs & has received FDA & EU’s approval combining Avastin(bevacizumab)+ paclitaxel + carboplatin & Avastin for metastatic nonsqNSCLC respectively

Ref: Roche | Image: Roche